Immunomedics Investigated For Securities Fraud By Block & Leviton After Revelation That Company Misrepresented Data At Important Conference

BOSTON, June 3, 2016 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Immunomedics Inc. (Nasdaq: IMMU) and its husband-and-wife executives David Goldenberg and Cynthia Sullivan have violated federal securities laws following the news today that the company misrepresented data at an important conference.

TheStreet.com reported that Immunomedics was caught "trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting, which starts on Friday." This data had already been presented in April, but was described by the executives as new and important. This news has caused Immunomedics shares to drop over 15% in pre-market trading this morning.

If you have recently purchased or otherwise acquired IMMU securities and have questions about your legal rights or possess information relevant to this investigation, please contact attorneys Jake Walker or Joel Fleming at (617) 398-5600 or by email at [email protected] or [email protected]. Confidentiality to whistleblowers or others with information relevant to the lawsuit is assured.

Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 70 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.

This notice may constitute attorney advertising.

CONTACT:
Block & Leviton LLP
Jacob Walker
155 Federal Street, Suite 400
Boston, MA 02110
(617) 398-5600
[email protected] 

SOURCE Block & Leviton LLP

Related Links

http://www.blockesq.com